Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO
Question
Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO
Direct answer
Doubling median overall survival to 15.8 months in the Cyclin E1 biomarker group de-risks regulatory approval paths for WEE1 inhibitor azenosertib, repricing ZNTL equity valuation. — bullish pressure on ZNTL via biomarker clinical survival de-risking registrational trial path.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-19
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO”, revision 1, evidence through 2026-10-19. https://marketontology.com/catalysts/2026-10-19/zentalis-reports-15-8-month-median-os-in-cyclin-e1-positive-ovarian-cancer-at-es-67ae4f
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ZNTL | ▲Bull | 1–5 days | biomarker clinical survival de-risking registrational trial path | 74 |
Zentalis Reports 15.8-Month Median OS in Cyclin E1-Positive Ovarian Cancer at ESMO
Doubling median overall survival to 15.8 months in the Cyclin E1 biomarker group de-risks regulatory approval paths for WEE1 inhibitor azenosertib, repricing ZNTL equity valuation. — bullish pressure on ZNTL via biomarker clinical survival de-risking registrational trial path.
DENALI Part 1b interim OS reached 15.8 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients.
- SourceDENALI Part 1b interim OS reached 15.8 months in Cyclin E1-positive patients versus 7.5 months in Cyclin E1-negative patients.
- TransmissionDoubling median overall survival to 15.8 months in the Cyclin E1 biomarker group de-risks regulatory approval paths for WEE1 inhibitor azenosertib, repricing ZNTL equity valuation.
- SummaryZentalis reported clinical survival data for azenosertib at ESMO 2026. Cyclin E1-positive ovarian cancer patients reached median overall survival of 15.8 months. Survival was more than double the 7.5 months observed in Cyclin E1-negative patients.
- ZNTLDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ZNTL closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ZNTL price vs. pre-event level
- ZNTL volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.